- Home
- TGTX vs RYN Comparison
TGTX vs RYN Comparison
Compare TGTX & RYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- RYN
- Stock Information
- Founded
- TGTX 1993
- RYN 1926
- Country
- TGTX United States
- RYN United States
- Employees
- TGTX N/A
- RYN N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- RYN Real Estate Investment Trusts
- Sector
- TGTX Health Care
- RYN Real Estate
- Exchange
- TGTX Nasdaq
- RYN Nasdaq
- Market Cap
- TGTX 5.4B
- RYN 4.5B
- IPO Year
- TGTX 1995
- RYN N/A
- Fundamental
- Price
- TGTX $32.91
- RYN $27.85
- Analyst Decision
- TGTX Strong Buy
- RYN Hold
- Analyst Count
- TGTX 6
- RYN 3
- Target Price
- TGTX $40.67
- RYN $33.67
- AVG Volume (30 Days)
- TGTX 2.3M
- RYN 571.8K
- Earning Date
- TGTX 11-04-2024
- RYN 01-29-2025
- Dividend Yield
- TGTX N/A
- RYN 10.52%
- EPS Growth
- TGTX N/A
- RYN 98.46
- EPS
- TGTX N/A
- RYN 1.07
- Revenue
- TGTX $264,790,000.00
- RYN $1,004,107,000.00
- Revenue This Year
- TGTX $43.74
- RYN N/A
- Revenue Next Year
- TGTX $64.30
- RYN N/A
- P/E Ratio
- TGTX N/A
- RYN $26.02
- Revenue Growth
- TGTX 39.53
- RYN 20.26
- 52 Week Low
- TGTX $12.84
- RYN $27.40
- 52 Week High
- TGTX $36.84
- RYN $35.29
- Technical
- Relative Strength Index (RSI)
- TGTX 55.20
- RYN 25.78
- Support Level
- TGTX $30.41
- RYN $28.33
- Resistance Level
- TGTX $35.03
- RYN $29.01
- Average True Range (ATR)
- TGTX 1.55
- RYN 0.56
- MACD
- TGTX -0.33
- RYN -0.39
- Stochastic Oscillator
- TGTX 51.78
- RYN 2.58
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.